A New Way to Administer Epinephrine – Introducing neffy®
ARS Pharmaceuticals Operations has recently introduced neffy® 2 mg, the first and only FDA-approved needle-free way to administer epinephrine. neffy® is a nasal spray used for emergency treatment of severe allergic reactions in adult and pediatric patients who weigh at least 66 pounds (30 kg). Per DailyMed, “the recommended dosage of neffy® is one spray (2 mg) administered in one nostril. In the absence of clinical improvement or if symptoms worsen after the initial treatment, a second dose of neffy® may be administered in the same nostril with a second nasal spray starting 5 minutes after the first dose.”
PAAS Tips:
- neffy® is for intranasal use only
- neffy® should NOT be primed
- 1 box (2 devices) is billed as 2 each
- Each box contains two single use devices each containing one dose (2 mg) of epinephrine
- A 1-day supply would be appropriate for billing purposes as it is recommended that patients are always prescribed, and have immediate access to, two neffy® nasal spray devices
- Refer to our updated Nasal Inhaler Chart on the Member Portal
- Pharmacies can utilize our 2024 Self-Audit Series #10: Nasal and Oral Inhaler Prescriptions to check for accuracy and consistency
- PBM Prescription Validation Requests – What Are They Looking At Now? - January 16, 2025
- Optimizing Prescriber Statements: Best Practices and Tips - January 8, 2025
- Adjusting Quantity or Days’ Supply Disproportionately Will Cost You! - December 24, 2024